Evidence map›Paper›PMID 39969694›Full record

Trial reportInternational journal of clinical oncology2025

Efficacy and safety of diffusing alpha-emitter radiation therapy (DaRT) for head and neck cancer recurrence after radiotherapy.

Ryo-Ichi Yoshimura, Kazuma Toda, Hiroshi Watanabe, Masahiko Miura, Ryoichi Notake, Naoya Murakami, Hiroshi Igaki, Satoshi Nakamura, Rei Umezawa, Noriyuki Kadoya and 2 more

Abstract readMulticenter StudyClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ryo-Ichi YoshimuraDepartment of Radiation Therapeutics and Oncology, Institute of Science Tokyo (Tokyo Medical and Dental University), 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan. ysmrmrad@tmd.ac.jp.ORCID http://orcid.org/0000-0001-9435-1503
Kazuma TodaDepartment of Radiation Therapeutics and Oncology, Institute of Science Tokyo (Tokyo Medical and Dental University), 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.
Hiroshi WatanabeDepartment of Dental Radiology and Radiation Oncology, Institute of Science Tokyo (Tokyo Medical and Dental University), Tokyo, Japan.
Masahiko MiuraDepartment of Dental Radiology and Radiation Oncology, Institute of Science Tokyo (Tokyo Medical and Dental University), Tokyo, Japan.
Ryoichi NotakeRadiology Center, Institute of Science Tokyo Hospital (Tokyo Medical Dental University Hospital), Tokyo, Japan.
Naoya MurakamiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hiroshi IgakiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Satoshi NakamuraDivision of Radiation Safety and Quality Assurance, National Cancer Center Hospital, Tokyo, Japan.
Rei UmezawaDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Noriyuki KadoyaDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Keiichi JinguDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Jun ItamiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate the efficacy and safety of diffusing alpha-emitter radiation therapy (DaRT) for recurrent head and neck cancer (rHNC) after radiotherapy.

methodsThis study was a multicenter prospective clinical trial. Eligibility criteria included all patients with biopsy-proven rHNC and history of radiotherapy. The efficacy of DaRT was evaluated in terms of tumor shrinkage after 10 weeks of DaRT seed implantation. To assess safety of DaRT, radioactivity levels in blood and urine were measured, and incidence and grade of adverse events (AEs) were evaluated.

resultsBetween 2019 and 2021, DaRT was performed in 11 patients and completed in 10 patients with 11 tumors. The tumor sites included the tongue (n = 3), buccal mucosa (2), lips (2), floor of the mouth (1), soft palate (1), nose (1), and subcutaneous layer (1). Nine tumors were confirmed to be squamous cell carcinoma, and the remaining two tumors were basal cell carcinoma and neuroblastoma. Complete response (CR) and partial response (PR) were observed in three and six patients, respectively. The response rate was 81.8%. The maximum average radioactivity levels in blood and urine were 42.5 Bq/cm

conclusionThe initial response of rHNC after radiotherapy to DaRT was favorable, and the incidence and grade of AEs were acceptable, as compared to existing therapies.

Indexed as

Alpha ParticlesBrachytherapyHead and Neck NeoplasmsNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeAdverse eventAlpha-emitter radiation therapyRecurrent head and neck cancerResponse rate

Identifiers

PMID39969694
PMCPMC12014721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.